Last10K.com

Ventas, Inc. (VTR) SEC Filing 8-K Material Event for the period ending Friday, August 6, 2021

Ventas Inc

CIK: 740260 Ticker: VTR
 
 Exhibit 99.1


Ventas Reports 2021 Second Quarter Results

CHICAGO--(BUSINESS WIRE)--August 6, 2021--Ventas, Inc. (NYSE: VTR) (“Ventas” or the “Company”) today reported results for the second quarter ended June 30, 2021.

“Ventas delivered strong second quarter results driven by outstanding sequential occupancy improvement and organic net operating income growth in our Senior Housing Operating Portfolio (“SHOP”) segment, Office growth and consistent and solid performance in our Triple Net (“NNN”) segment,” said Debra A. Cafaro, Ventas Chairman and CEO.

“Ventas’s organic growth potential and external investment opportunities combine to create attractive upside for our stakeholders. We have now delivered five consecutive months of growth in occupancy and leads in SHOP, with June move-ins and July leads representing the highest levels since the onset of the pandemic. These positive trends underscore the strong demand for the socialization and services our communities provide. Senior housing is entering a period of highly favorable conditions as occupancy rebounds and supply demand fundamentals improve. In the face of renewed macro clinical uncertainty, we remain optimistic with all our SHOP communities benefitting from extremely high COVID-19 vaccination rates among our residents and staff.

“We are confident about the future of our business, the powerful senior housing cyclical upside and our ability to win the recovery with our advantaged, well diversified portfolio, best-in-class operators and experienced team,” Cafaro concluded.

Second Quarter 2021 Results

For the second quarter 2021, reported per share results were:

 

Quarter Ended June 30

 

2021

2020

$ Change

% Change

Net Income (Loss) Attributable to Common Stockholders

$0.23

($0.42)

$0.65

155%

Nareit FFO Attributable to Common Stockholders (“Nareit FFO”)*

$0.78

$0.50

$0.28

56%

Normalized FFO Attributable to Common Stockholders (“Normalized FFO”)*

$0.73

$0.77

($0.04)

(5%)

 

 

 

 

 

*

This is a non-GAAP financial measure. Refer to the Non-GAAP Financial Measures Reconciliation tables at the end of this press release for additional information and a reconciliation to the most directly comparable GAAP measure.


Second Quarter 2021 Property Results


 

 

2Q21 vs. 2Q20 (Quarterly Pools)
Year-Over-Year

Same-Store Cash Net Operating
Income (“NOI”)* Growth

 

 

 

Assets

% Change

 

SHOP

 

393

(12.0%)

 

NNN

 

352

(12.2%)

 

Office

 

345

12.6%

 

Total Company

 

1,090

(4.6%)

 

 

 

 

 

 

 

 

 

2Q21 vs. 1Q21 (Sequential Pools)
Sequential
Same-Store Cash NOI* Growth

 

 

 

Assets

% Change

 

SHOP1

 

434

(0.7%)

 

NNN

 

355

(0.2%)

 

Office

 

346

10.5%

 

Total Company

 

1,135

3.1%

 

 

 

 

 

 

*

This is a non-GAAP financial measure. Refer to the Non-GAAP Financial Measures Reconciliation tables at the end of this press release for additional information and a reconciliation to the most directly comparable GAAP measure.

1.

12.6% SHOP Same-Store Cash NOI sequential growth when excluding the HHS Grants received in 1Q21. SHOP Same-Store Cash NOI includes grants totaling $13.3 million received in 1Q21 under the Provider Relief Fund administered by the Department of Health and Human Services (the “HHS Grants”). The HHS Grants are recorded as a contra expense within SHOP operating expenses.

Sequential Same-Store Property Results

  • Company Results
    • Sequential same-store second quarter 2021 cash NOI increased 3.1%, or 3.6% excluding the impact of $13.3 million of HHS Grants in the first quarter 2021 and a $12 million cash lease termination fee received in the Life Science, Research & Innovation (“Life Science, R&I”) portfolio in the second quarter.
  • SHOP (26% of Total Portfolio)
    • NOI: SHOP NOI totaled $111 million in the second quarter. Same-store cash NOI in second quarter 2021 increased $50 million on an annualized basis compared to first quarter 2021 excluding HHS Grants received in the first quarter.
      • Sequential same-store pool (434 assets) cash NOI increased 12.6% excluding the HHS Grants received in the first quarter. Including the HHS Grants, sequential same-store cash NOI decreased by 0.7%.
    • Occupancy and Leading Indicators:
      • Leads and move-ins in June were the highest since the onset of the pandemic, with leads reaching 106% of pre-pandemic levels and move-ins approximating 2,100 residents.
      • Ventas’s SHOP portfolio experienced a 229 basis point increase in approximate spot occupancy from March 31 to June 30, led by U.S. SHOP communities, substantially better than the midpoint of our previously communicated expectation of up 150 to 250 basis points.
      • Average SHOP occupancy grew 110 basis points in the second quarter versus the first quarter 2021.
      • U.S. SHOP portfolio increased 313 basis points in approximate spot occupancy from March 31 to June 30.
      • Approximate spot-to-spot occupancy in our Canada SHOP portfolio increased in the second quarter driven by a positive June occupancy trend. Canada recently surpassed the U.S. in vaccinations amongst its adult population.
      • SHOP second quarter average and quarter-end occupancy were 77.5% and 79.4%, respectively.

(2Q2021 sequential pool of 434 assets)

Feb-21

Mar-21

Apr-21

May-21

Jun-21

March 31 to
June 30

Approximate Spot Occupancy

76.5%

77.1%

77.7%

78.4%

79.4%

--

Sequential Spot Occupancy Change – Total

(26bps)

+57bps

+69bps

+68bps

+92bps

+229bps

Sequential Spot Occupancy Change – U.S.

(25bps)

+87bps

+102bps

+96bps

+115bps

+313bps

Sequential Spot Occupancy Change – Canada

(30bps)

(18bps)

(15bps)

(2bps)

+33bps

+17bps

  • Revenue: SHOP revenue increased in the second quarter driven by an increase in occupancy, which was partially offset by move-in incentives provided to new residents.
  • Operating Expenses: Operating expenses declined sequentially by $9.2 million, excluding the HHS Grants received in the first quarter (which were reflected as a contra expense when received), driven by a better than expected reduction of COVID-19 costs partially offset by a modest increase in routine operating expenses. Including the impact of HHS Grants, operating expenses grew $4.1 million.
NNN Portfolio (37% of Total Portfolio)
o
NNN sequential same-store (355 assets) cash NOI was stable in the second quarter 2021. All expected second quarter rent was received from the Company’s NNN tenants.
Office Portfolio (32% of Total Portfolio)
o
Office sequential same-store pool (346 assets) cash NOI grew by 10.5%, led by the Life Science, R&I portfolio. Life Science, R&I benefitted from a $12 million cash lease termination fee received in the second quarter, which is included in second quarter cash NOI and amortized over the remaining twelve-month lease term on a GAAP basis. Office sequential same-store cash NOI growth was 0.9% when adjusted for this fee. Steady growth of the Medical Office Building (“MOB”) business continued in the second quarter with outstanding customer retention of 94% and new leasing of 190,000 square feet, resulting in a total MOB portfolio sequential occupancy increase of 20 basis points.

Latest SHOP Operating Trends

  • Leading Indicators: Leading indicators and demand showed continued strength in July:
    • Leads were 105% of their pre-COVID-19 same period 2019 level at over 21,300, a new high. Move-ins and move-outs were 112% and 85% respectively of their pre-COVID-19 same period 2019 levels.
    • Move-ins totaled 2,017 residents.
    • Move-ins have exceeded 2,000 for three consecutive months.
  • Occupancy: Ventas’s SHOP portfolio has now experienced a five consecutive month trend of occupancy growth. Spot occupancy has increased 424 basis points from the pandemic low reached in mid-March through July 31, 2021.
    • The SHOP portfolio reported 74 basis points of approximate spot occupancy increase from June 30 through July 31, 2021, with the U.S. growing 84 basis points and Canada growth improving to 47 basis points in the month.
  • Clinical Trends: The Company’s SHOP communities continue to experience de minimis confirmed resident cases of COVID-19, with high vaccination rates among residents and staff members.

Investments in Ardent

  • Ardent continues to deliver strong performance as an industry-leading owner and operator of 30 hospitals in six states and Ventas’s $1.4 billion investment in Ardent real estate is currently yielding over 9% with strong 3.6x trailing twelve month cash flow coverage.
  • In addition, Ventas’s 10% equity interest in Ardent, in partnership with Equity Group Investments, and Ventas’s prior investment in $200 million of Ardent 2026 Senior Notes (defined below), continue to provide significant benefits to Ventas.
    • In the second quarter, Ventas benefitted from Ardent’s strong performance and recognition of HHS Grants which was approximately $7 million at Ventas’s share.
    • In July 2021, Ardent redeemed Ventas’s investment in $200 million of 9.75% senior notes due 2026 (the “Ardent 2026 Senior Notes”), in connection with Ardent’s successful offering of newly issued senior notes at a coupon of 5.75%. In addition to repayment of principal in full, Ventas received $15 million in prepayment premium, as required by Ardent’s 2026 Senior Notes. The redemption, including the prepayment premium, will be recognized in the third quarter. Ventas’s investment in the Ardent 2026 Senior Notes yielded a 13% unlevered IRR.

Capital Allocation

  • Ventas’s total 2021 investments completed or announced to date are $2.6 billion. The Company also has $1.1 billion of ongoing development principally in the Life Science, R&I and Canadian senior housing markets. In addition, the Company also has a forward pipeline of approximately $1 billion in Life Science, R&I projects.
  • On June 28, 2021, Ventas announced that it had entered into a definitive merger agreement pursuant to which Ventas will acquire New Senior (NYSE: SNR) in an all-stock transaction valued at approximately $2.3 billion, including $1.5 billion of New Senior debt. Under the terms of the agreement, New Senior stockholders will receive 0.1561 shares of newly issued Ventas common stock for each share of New Senior common stock they own. Completion of the transaction, which is expected to occur during the second half of this year, is subject to the satisfaction of customary closing conditions, including the approval by the common stockholders of New Senior.
  • Ventas also extended its successful track record of development with its partner Le Groupe Maurice (“LGM”):
    • On June 1, 2021, Ventas and LGM opened a new, 287-unit development, in Montreal known as Elogia II, which already reached 50% occupancy as of July 31. This property was developed adjacent to an existing 289-unit LGM property and joined via connecting bridge. Due to the proximity and physical connectivity, residents of both buildings will enjoy LGM’s signature state-of-the-art amenities, including beautiful gardens, fitness facilities, a movie theatre, a light therapy room, an indoor swimming pool, an expansive rooftop and a panoramic lounge with views of Montreal’s skyline.
    • Two LGM development properties opened in the fourth quarter of 2020 continue to enjoy robust demand and are currently 94% occupied.
    • Two additional development projects are underway totaling over $200 million in project costs and spanning 627 units, with additional sites in the pre-development stage.
  • Ventas is in advanced stages for a Life Science, R&I development project anchored by a premier research university. The project, which is principally lab space and related uses, will be 60% pre-leased. Project costs approximate $0.5 billion with an expected stabilized cash yield between 6.5% and 7.0%. The university tenant is ranked in the top 5% of universities for both NIH funding and R&D spend. The development is one of the pre-identified Life Science, R&I development projects that is eligible for inclusion in the attractive R&I development partnership with GIC.
  • The Company continues to enhance the quality of its portfolio through asset sales and to receive repayment of high return, well-structured loans. Year to date through August 5, 2021, the Company has received nearly $450M of disposition proceeds, including these Recent Dispositions:
    • Ardent’s redemption in July 2021 of Ventas’s investment in $200 million of Ardent 2026 Senior Notes, along with a $15 million prepayment premium as described above.
    • Holiday’s full repayment in July of $66 million of 9.4% notes due 2025. Ventas originally received the notes along with $34 million of cash as consideration for the conversion of 26 Holiday-operated independent living communities from a NNN lease to a SHOP operating model in the second quarter of 2020.
    • Two MOBs sold during the second quarter for total proceeds of approximately $107 million.

Financial Strength & Liquidity

  • As of August 5, 2021, the Company has robust liquidity of $3.3 billion, including $2.7 billion of undrawn revolver capacity, $0.6 billion in cash and cash equivalents on hand, and no commercial paper outstanding.
    • For the second quarter 2021, Ventas’s Net Debt to Adjusted Pro Forma EBITDA ratio was 7.0x, a sequential improvement of 10 basis points from the first quarter. Total Indebtedness to Gross Asset Value was stable at 37% in the second quarter 2021.
    • During and subsequent to the second quarter, the Company received $300 million in gross proceeds under its “at the market” equity offering program, totaling 5.2 million shares of common stock sold at an average gross price of $58.56 per share in anticipation of the closing of the New Senior transaction.
    • Using proceeds from Recent Dispositions, Ventas will fully repay $664 million in aggregate principal amount of outstanding senior notes. On August 16, 2021, the Company will retire $264 million aggregate principal amount of 3.25% senior notes due August 2022 and on September 1, 2021, the Company will retire $400 million aggregate principal amount of 3.125% senior notes due June 2023.

Second Quarter Dividend

The Company paid its second quarter 2021 dividend of $0.45 per share on July 14, 2021 to stockholders of record as of July 1, 2021.

Third Quarter 2021 Guidance

The Company currently expects to report third quarter 2021 Net Income (Loss) Attributable to Common Stockholders, Nareit FFO and Normalized FFO within the following per share ranges:

 

 

3Q21 Guidance

 

 

Per Share

 

 

Low

 

High

 

 

 

 

 

Net Income (Loss) Attributable to Common Stockholders

 

$0.00

-

$0.05

Nareit FFO*

 

$0.61

-

$0.65

Normalized FFO*

 

$0.70

-

$0.74

*

This is a non-GAAP financial measure. Refer to the Non-GAAP Financial Measures Reconciliation tables at the end of this press release for additional information and a reconciliation to the most directly comparable GAAP measure


Key assumptions underlying the third quarter 2021 guidance include, among other things:

  • Approximate spot occupancy in the Company’s sequential same-store SHOP business is assumed to increase 150 – 250 basis points from June 30, 2021 to September 30, 2021, creating revenue growth, which is expected to be approximately offset by increasing operating costs due to an additional day in the quarter, higher occupancy, labor, routine seasonal items and potential COVID-19 related expenditures.
  • No HHS Grants are assumed to be received in the third quarter.
  • A net benefit in the third quarter compared to the second quarter of two cents from “Ardent Activities”. Specifically, recognition of the receipt by Ventas of a $15 million prepayment fee in connection with Ardent’s redemption of the Ardent 2026 Senior Notes in the third quarter, net of $7 million (at Ventas’s share) of HHS Grants recognized by Ardent in the second quarter.
  • Stable performance in the Office and NNN segments.
  • Fully diluted share count of 383 million shares reflecting the equity raised in July.
  • The Company continues to expect a total of approximately $1.0 billion in asset sales and loan repayments in 2021 principally in senior housing and medical office properties with proceeds used to reduce near term indebtedness and to fund investment in development.
  • No material changes in the impact of COVID-19 on our business. The trajectory and future impact of the COVID-19 pandemic, including the impact of the Delta or any other variant, remain highly uncertain and may change rapidly. The extent of the pandemic’s continuing and ultimate effect on our operational and financial performance will depend on a variety of factors, including the speed at which vaccines and other clinical treatments are successfully developed and deployed. Significant changes or impacts of the pandemic are excluded from our guidance.
  • The Company’s current third quarter 2021 guidance excludes any contribution or impact from the pending acquisition of New Senior, which is expected to close during the second half of this year.

Other third quarter 2021 assumptions are set forth below:

 

 

Increase / (Decrease) to
Normalized FFO/sh.

 

 

3Q21 Guidance Midpoint

 

 

vs. 2Q21 Actuals

2Q21 Normalized FFO*

 

$0.73

Ardent Activities

 

0.02

Equity Raised and Recent Dispositions

 

(0.02)

NOI from Properties Intended for Disposition

 

(0.01)

3Q21 Normalized FFO* Guidance Midpoint

 

$0.72

*

This is a non-GAAP financial measure. Refer to the Non-GAAP Financial Measures Reconciliation tables at the end of this press release for additional information and a reconciliation to the most directly comparable GAAP measure.

A presentation outlining the Company’s second quarter results and business update is posted to the Events & Presentations section of Ventas’s website at ir.ventasreit.com/events-and-presentations. Additional information regarding the Company can be found in its second quarter 2021 supplemental posted at ir.ventasreit.com. The information contained on, or that may be accessed through, our website is not incorporated by any reference into, and is not part of, this document.

Second Quarter 2021 Results Conference Call

Ventas will hold a conference call to discuss this earnings release today at 10:00 a.m. Eastern Time (9:00 a.m. Central Time).

The dial-in number for the conference call is (833) 968-1984 (or +1 (778) 560-2824 for international callers), and the participant passcode is 1487218. A live webcast can be accessed from the Investor Relations section of www.ventasreit.com.

A telephonic replay will be available at (800) 585-8367 (or +1 (416) 621-4642 for international callers), passcode 1487218, after the earnings call and will remain available for 30 days. The webcast replay will be posted in the Investor Relations section of www.ventasreit.com.

About Ventas

Ventas, an S&P 500 company, operates at the intersection of two powerful and dynamic industries – healthcare and real estate. As one of the world’s foremost Real Estate Investment Trusts (REIT), we use the power of capital to unlock the value of real estate, partnering with leading care providers, developers, research and medical institutions, innovators and healthcare organizations whose success is buoyed by the demographic tailwind of an aging population. For more than twenty years, Ventas has followed a successful strategy that endures: combining a high-quality diversified portfolio of properties and capital sources to manage through cycles, working with industry leading partners, and a collaborative and experienced team focused on producing consistent growing cash flows and superior returns on a strong balance sheet, ultimately rewarding Ventas stakeholders. As of June 30, 2021, Ventas owned or had investments in approximately 1,200 properties.


Non-GAAP Financial Measures

This press release includes certain financial performance measures not defined by generally accepted accounting principles in the Unites States (“GAAP”). Reconciliations of these non-GAAP financial measures to the most directly comparable GAAP measures are included in this press release. We believe such measures provide investors with additional information concerning our operating performance and a basis to compare our performance with the performance of other REITs. Our definitions and calculations of these non-GAAP measures may not be the same as similar measures reported by other REITs.

These non-GAAP financial measures should not be considered as alternatives to net income attributable to common stockholders (determined in accordance with GAAP) as indicators of our financial performance or as alternatives to cash flow from operating activities (determined in accordance with GAAP) as measures of our liquidity, nor are these measures necessarily indicative of sufficient cash flow to fund all of our needs.

Cautionary Statements

Certain of the information contained herein, including intra-quarter operating information and number of confirmed cases of COVID-19, has been provided by our operators and we have not verified this information through an independent investigation or otherwise. We have no reason to believe that this information is inaccurate in any material respect, but we cannot assure you of its accuracy.

This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among others, statements of expectations, beliefs, future plans and strategies, anticipated results from operations and developments and other matters that are not historical facts. Forward-looking statements include, among other things, statements regarding our and our officers’ intent, belief or expectation as identified by the use of words such as “may,” “will,” “project,” “expect,” “believe,” “intend,” “anticipate,” “seek,” “target,” “forecast,” “plan,” “potential,” “estimate,” “could,” “would,” “should” and other comparable and derivative terms or the negatives thereof.

Forward-looking statements are based on management’s beliefs as well as on a number of assumptions concerning future events. You should not put undue reliance on these forward-looking statements, which are not a guarantee of performance and are subject to a number of uncertainties and other factors that could cause actual events or results to differ materially from those expressed or implied by the forward-looking statements. You are urged to carefully review the disclosures we make concerning risks and uncertainties that may affect our business and future financial performance in our filings with the Securities and Exchange Commission, including those made in the “Risk Factors” section and “Management’s Discussion & Analysis of Financial Condition and Results of Operations” section of our most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q. We do not undertake a duty to update these forward-looking statements, which speak only as of the date on which they are made.


Certain factors that could affect our future results and our ability to achieve our stated goals include, but are not limited to: (a) the impact of the ongoing COVID-19 pandemic, including of the Delta or any other variant, on our revenue, level of profitability, liquidity and overall risk exposure and the implementation and impact of regulations related to the CARES Act and other stimulus legislation and any future COVID-19 relief measures; (b) our ability to achieve the anticipated benefits and synergies from the proposed acquisition of, and the risk of greater than expected costs or other difficulties related to the integration of, New Senior and the cost of capital to fund the acquisition and any debt paydown; (c) the proposed acquisition of New Senior may not be completed on the currently contemplated timeline or terms, or at all; (d) our exposure and the exposure of our tenants, borrowers and managers to complex healthcare and other regulation and the challenges and expense associated with complying with such regulation; (e) the potential for significant general and commercial claims, legal actions, regulatory proceedings or enforcement actions that could subject us or our tenants, borrowers or managers to increased operating costs and uninsured liabilities; (f) the impact of market and general economic conditions, including economic and financial market events, or events that affect consumer confidence, our occupancy rates and resident fee revenues, and the actual and perceived state of the real estate markets, labor markets and public capital markets; (g) our ability, and the ability of our tenants, borrowers and managers, to navigate the trends impacting our or their businesses and the industries in which we or they operate; (h) the risk of bankruptcy, insolvency or financial deterioration of our tenants, borrowers, managers and other obligors and our ability to foreclose successfully on the collateral securing our loans and other investments in the event of a borrower default; (i) our ability to identify and consummate future investments in or dispositions of healthcare assets and effectively manage our portfolio opportunities and our investments in co-investment vehicles; (j) our ability to attract and retain talented employees; (k) the limitations and significant requirements imposed upon our business as a result of our status as a REIT and the adverse consequences (including the possible loss of our status as a REIT) that would result if we are not able to comply; (l) the risk of changes in healthcare law or regulation or in tax laws, guidance and interpretations, particularly as applied to REITs, that could adversely affect us or our tenants, borrowers or managers; (m) increases in the Company’s borrowing costs as a result of becoming more leveraged or as a result of changes in interest rates and phasing out of LIBOR rates; (n) our reliance on third parties to operate a majority of our assets and our limited control and influence over such operations and results; (o) our dependency on a limited number of tenants and managers for a significant portion of our revenues and operating income; (p) the adequacy of insurance coverage provided by our policies and policies maintained by our tenants, managers or other counterparties; (q) the occurrence of cyber incidents that could disrupt our operations, result in the loss of confidential information or damage our business relationships and reputation; (r) the impact of merger, acquisition and investment activity in the healthcare industry or otherwise affecting our tenants, borrowers or managers; and (s) the risk of catastrophic or extreme weather and other natural events and the physical effects of climate change.


 

CONSOLIDATED BALANCE SHEETS

(In thousands, except per share amounts; dollars in USD)

(unaudited)

 

 

 

 

 

 

 

 

 

 

 

June 30,

 

March 31,

 

December 31,

 

September 30,

 

June 30,

 

2021

 

2021

 

2020

 

2020

 

2020

 

 

 

 

 

 

 

 

 

 

Assets

 

 

 

 

 

 

 

 

 

Real estate investments:

 

 

 

 

 

 

 

 

 

Land and improvements

$

2,231,836

 

 

$

2,235,773

 

 

$

2,261,415

 

 

$

2,268,583

 

 

$

2,258,699

 

Buildings and improvements

24,269,450

 

 

24,250,630

 

 

24,323,279

 

 

24,196,730

 

 

23,964,691

 

Construction in progress

288,910

 

 

310,547

 

 

265,748

 

 

567,052

 

 

496,349

 

Acquired lease intangibles

1,200,574

 

 

1,212,263

 

 

1,230,886

 

 

1,246,312

 

 

1,242,414

 

Operating lease assets

328,707

 

 

343,072

 

 

346,372

 

 

386,946

 

 

389,302

 

 

28,319,477

 

 

28,352,285

 

 

28,427,700

 

 

28,665,623

 

 

28,351,455

 

Accumulated depreciation and amortization

(8,189,447

)

 

(8,030,524

)

 

(7,877,665

)

 

(7,687,211

)

 

(7,453,251

)

Net real estate property

20,130,030

 

 

20,321,761

 

 

20,550,035

 

 

20,978,412

 

 

20,898,204

 

Secured loans receivable and investments, net

596,171

 

 

615,037

 

 

605,567

 

 

604,452

 

 

681,831

 

Investments in unconsolidated real estate entities

494,239

 

 

471,243

 

 

443,688

 

 

162,860

 

 

166,039

 

Net real estate investments

21,220,440

 

 

21,408,041

 

 

21,599,290

 

 

21,745,724

 

 

21,746,074

 

Cash and cash equivalents

233,837

 

 

169,661

 

 

413,327

 

 

588,343

 

 

992,824

 

Escrow deposits and restricted cash

40,931

 

 

40,551

 

 

38,313

 

 

40,147

 

 

36,312

 

Goodwill

1,051,832

 

 

1,051,780

 

 

1,051,650

 

 

1,050,742

 

 

1,050,115

 

Assets held for sale

90,002

 

 

59,860

 

 

9,608

 

 

15,748

 

 

76,021

 

Deferred income tax assets, net

11,486

 

 

11,610

 

 

9,987

 

 

304

 

 

304

 

Other assets

855,786

 

 

810,760

 

 

807,229

 

 

779,475

 

 

687,738

 

Total assets

$

23,504,314

 

 

$

23,552,263

 

 

$

23,929,404

 

 

$

24,220,483

 

 

$

24,589,388

 

 

 

 

 

 

 

 

 

 

 

Liabilities and equity

 

 

 

 

 

 

 

 

 

Liabilities:

 

 

 

 

 

 

 

 

 

Senior notes payable and other debt

$

11,761,545

 

 

$

11,759,299

 

 

$

11,895,412

 

 

$

12,047,919

 

 

$

12,530,036

 

Accrued interest

105,883

 

 

91,390

 

 

111,444

 

 

97,828

 

 

117,687

 

Operating lease liabilities

205,484

 

 

206,426

 

 

209,917

 

 

247,255

 

 

248,912

 

Accounts payable and other liabilities

1,122,171

 

 

1,109,279

 

 

1,133,066

 

 

1,234,933

 

 

998,446

 

Liabilities related to assets held for sale

4,568

 

 

3,853

 

 

3,246

 

 

1,987

 

 

5,514

 

Deferred income tax liabilities

68,097

 

 

65,777

 

 

62,638

 

 

53,711

 

 

56,963

 

Total liabilities

13,267,748

 

 

13,236,024

 

 

13,415,723

 

 

13,683,633

 

 

13,957,558

 

 

 

 

 

 

 

 

 

 

 

Redeemable OP unitholder and noncontrolling interests

252,662

 

 

244,619

 

 

235,490

 

 

249,143

 

 

231,920

 

 

 

 

 

 

 

 

 

 

 

Commitments and contingencies

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Equity:

 

 

 

 

 

 

 

 

 

Ventas stockholders’ equity:

 

 

 

 

 

 

 

 

 

Preferred stock, $1.00 par value; 10,000 shares authorized, unissued

 

 

 

 

 

 

 

 

 

Common stock, $0.25 par value; 375,204; 375,068; 374,609; 373,940; and 373,113 shares issued at June 30, 2021, March 31, 2021, December 31, 2020, September 30, 2020 and June 30, 2020, respectively

93,784

 

 

93,750

 

 

93,635

 

 

93,467

 

 

93,261

 

Capital in excess of par value

14,187,577

 

 

14,186,692

 

 

14,171,262

 

 

14,142,349

 

 

14,118,119

 

Accumulated other comprehensive loss

(58,290

)

 

(52,497

)

 

(54,354

)

 

(65,042

)

 

(82,761

)

Retained earnings (deficit)

(4,340,052

)

 

(4,257,001

)

 

(4,030,376

)

 

(3,972,647

)

 

(3,816,460

)

Treasury stock, 6; 14; 0; 33; and 24 shares at June 30, 2021, March 31, 2021, December 31, 2020, September 30, 2020 and June 30, 2020, respectively

(320

)

 

(789

)

 

 

 

(1,275

)

 

(947

)

Total Ventas stockholders’ equity

9,882,699

 

 

9,970,155

 

 

10,180,167

 

 

10,196,852

 

 

10,311,212

 

Noncontrolling interests

101,205

 

 

101,465

 

 

98,024

 

 

90,855

 

 

88,698

 

Total equity

9,983,904

 

 

10,071,620

 

 

10,278,191

 

 

10,287,707

 

 

10,399,910

 

Total liabilities and equity

$

23,504,314

 

 

$

23,552,263

 

 

$

23,929,404

 

 

$

24,220,483

 

 

$

24,589,388

 




















 


CONSOLIDATED STATEMENTS OF INCOME

(In thousands, except per share amounts; dollars in USD)

(unaudited)

 

 

 

 

 

 

 

 

 

For the Three Months Ended

 

For the Six Months Ended

 

June 30,

 

June 30,

 

2021

 

2020

 

2021

 

2020

Revenues

 

 

 

 

 

 

 

Rental income:

 

 

 

 

 

 

 

Triple-net leased

$

159,223

 

 

$

176,240

 

 

$

319,108

 

 

$

371,102

 

Office

200,388

 

 

192,925

 

 

397,843

 

 

401,320

 

 

359,611

 

 

369,165

 

 

716,951

 

 

772,422

 

Resident fees and services

535,952

 

 

549,329

 

 

1,064,602

 

 

1,126,099

 

Office building and other services revenue

5,381

 

 

3,673

 

 

10,331

 

 

6,801

 

Income from loans and investments

17,665

 

 

19,491

 

 

36,675

 

 

43,537

 

Interest and other income

585

 

 

1,540

 

 

926

 

 

6,393

 

Total revenues

919,194

 

 

943,198

 

 

1,829,485

 

 

1,955,252

 

Expenses

 

 

 

 

 

 

 

Interest

110,051

 

 

123,132

 

 

220,818

 

 

239,828

 

Depreciation and amortization

250,700

 

 

349,594

 

 

564,848

 

 

598,431

 

Property-level operating expenses:

 

 

 

 

 

 

 

Senior living

424,813

 

 

432,578

 

 

842,642

 

 

842,709

 

Office

64,950

 

 

60,752

 

 

128,896

 

 

125,258

 

Triple-net leased

4,432

 

 

5,275

 

 

9,257

 

 

11,606

 

 

494,195

 

 

498,605

 

 

980,795

 

 

979,573

 

Office building services costs

658

 

 

543

 

 

1,276

 

 

1,270

 

General, administrative and professional fees

30,588

 

 

28,080

 

 

70,897

 

 

68,540

 

(Gain) loss on extinguishment of debt, net

(74

)

 

 

 

27,016

 

 

 

Merger-related expenses and deal costs

721

 

 

6,586

 

 

5,338

 

 

14,804

 

Allowance on loans receivable and investments

(59

)

 

29,655

 

 

(8,961

)

 

29,655

 

Other

(13,490

)

 

5,286

 

 

(22,918

)

 

11,069

 

Total expenses

873,290

 

 

1,041,481

 

 

1,839,109

 

 

1,943,170

 

Income (loss) before unconsolidated entities, real estate

dispositions, income taxes and noncontrolling interests

45,904

 

 

(98,283

)

 

(9,624

)

 

12,082

 

Income (loss) from unconsolidated entities

4,767

 

 

(5,850

)

 

4,517

 

 

(16,726

)

Gain on real estate dispositions

41,258

 

 

1,254

 

 

43,791

 

 

227,479

 

Income tax (expense) benefit

(3,641

)

 

(56,356

)

 

(5,794

)

 

92,660

 

Income (loss) from continuing operations

88,288

 

 

(159,235

)

 

32,890

 

 

315,495

 

Net income (loss)

88,288

 

 

(159,235

)

 

32,890

 

 

315,495

 

Net income (loss) attributable to noncontrolling interests

1,897

 

 

(2,065

)

 

3,708

 

 

(452

)

Net income (loss) attributable to common stockholders

$

86,391

 

 

$

(157,170

)

 

$

29,182

 

 

$

315,947

 

Earnings per common share

 

 

 

 

 

 

 

Basic:

 

 

 

 

 

 

 

Income (loss) from continuing operations

$

0.24

 

 

$

(0.43

)

 

$

0.09

 

 

$

0.85

 

Net income (loss) attributable to common stockholders

0.23

 

 

(0.42

)

 

0.08

 

 

0.85

 

Diluted:1

 

 

 

 

 

 

 

Income (loss) from continuing operations

$

0.23

 

 

$

(0.43

)

 

$

0.09

 

 

$

0.84

 

Net income (loss) attributable to common stockholders

0.23

 

 

(0.42

)

 

0.08

 

 

0.84

 

 

 

 

 

 

 

 

 

Weighted average shares used in computing earnings per common share

 

 

 

 

 

 

 

Basic

375,067

 

 

372,982

 

 

374,869

 

 

372,905

 

Diluted

378,408

 

 

376,024

 

 

378,161

 

 

376,020

 


 

1Potential common shares are not included in the computation of diluted earnings per share when a loss from continuing operations exists as the effect would be an antidilutive per share amount.



 

QUARTERLY CONSOLIDATED STATEMENTS OF INCOME

(In thousands, except per share amounts; dollars in USD)

(unaudited)

 

 

 

 

 

 

 

 

 

 

 

For the Three Months Ended

 

June 30,

 

March 31,

 

December 31,

 

September 30,

 

June 30,

 

2021

 

2021

 

2020

 

2020

 

2020

Revenues

 

 

 

 

 

 

 

 

 

Rental income:

 

 

 

 

 

 

 

 

 

Triple-net leased

$

159,223

 

 

$

159,885

 

 

$

168,027

 

 

$

156,136

 

 

$

176,240

 

Office

200,388

 

 

197,455

 

 

199,931

 

 

198,376

 

 

192,925

 

 

359,611

 

 

357,340

 

 

367,958

 

 

354,512

 

 

369,165

 

Resident fees and services

535,952

 

 

528,650

 

 

529,739

 

 

541,322

 

 

549,329

 

Office building and other services revenue

5,381

 

 

4,950

 

 

4,522

 

 

3,868

 

 

3,673

 

Income from loans and investments

17,665

 

 

19,010

 

 

18,302

 

 

18,666

 

 

19,491

 

Interest and other income

585

 

 

341

 

 

644

 

 

572

 

 

1,540

 

Total revenues

919,194

 

 

910,291

 

 

921,165

 

 

918,940

 

 

943,198

 

 

 

 

 

 

 

 

 

 

 

Expenses

 

 

 

 

 

 

 

 

 

Interest

110,051

 

 

110,767

 

 

114,208

 

 

115,505

 

 

123,132

 

Depreciation and amortization

250,700

 

 

314,148

 

 

261,966

 

 

249,366

 

 

349,594

 

Property-level operating expenses:

 

 

 

 

 

 

 

 

 

Senior living

424,813

 

 

417,829

 

 

393,309

 

 

422,653

 

 

432,578

 

Office

64,950

 

 

63,946

 

 

64,420

 

 

66,934

 

 

60,752

 

Triple-net leased

4,432

 

 

4,825

 

 

5,156

 

 

5,398

 

 

5,275

 

 

494,195

 

 

486,600

 

 

462,885

 

 

494,985

 

 

498,605

 

Office building services costs

658

 

 

618

 

 

488

 

 

557

 

 

543

 

General, administrative and professional fees

30,588

 

 

40,309

 

 

29,537

 

 

32,081

 

 

28,080

 

(Gain) loss on extinguishment of debt, net

(74

)

 

27,090

 

 

3,405

 

 

7,386

 

 

 

Merger-related expenses and deal costs

721

 

 

4,617

 

 

3,683

 

 

11,325

 

 

6,586

 

Allowance on loans receivable and investments

(59

)

 

(8,902

)

 

(10,416

)

 

4,999

 

 

29,655

 

Other

(13,490

)

 

(9,428

)

 

(16,043

)

 

5,681

 

 

5,286

 

Total expenses

873,290

 

 

965,819

 

 

849,713

 

 

921,885

 

 

1,041,481

 

 

 

 

 

 

 

 

 

 

 

Income (loss) before unconsolidated entities, real estate dispositions, income taxes and noncontrolling interests

45,904

 

 

(55,528

)

 

71,452

 

 

(2,945

)

 

(98,283

)

Income (loss) from unconsolidated entities

4,767

 

 

(250

)

 

17,705

 

 

865

 

 

(5,850

)

Gain on real estate dispositions

41,258

 

 

2,533

 

 

22,117

 

 

12,622

 

 

1,254

 

Income tax (expense) benefit

(3,641

)

 

(2,153

)

 

679

 

 

3,195

 

 

(56,356

)

Income (loss) from continuing operations

88,288

 

 

(55,398

)

 

111,953

 

 

13,737

 

 

(159,235

)

Net income (loss)

88,288

 

 

(55,398

)

 

111,953

 

 

13,737

 

 

(159,235

)

Net income (loss) attributable to noncontrolling interests

1,897

 

 

1,811

 

 

1,502

 

 

986

 

 

(2,065

)

Net income (loss) attributable to common stockholders

$

86,391

 

 

$

(57,209

)

 

$

110,451

 

 

$

12,751

 

 

$

(157,170

)

 

 

 

 

 

 

 

 

 

 

Earnings per common share

 

 

 

 

 

 

 

 

 

Basic:

 

 

 

 

 

 

 

 

 

Income (loss) from continuing operations

$

0.24

 

 

$

(0.15

)

 

$

0.30

 

 

$

0.04

 

 

$

(0.43

)

Net income (loss) attributable to common stockholders

0.23

 

 

(0.15

)

 

0.29

 

 

0.03

 

 

(0.42

)

Diluted:1

 

 

 

 

 

 

 

 

 

Income (loss) from continuing operations

$

0.23

 

 

$

(0.15

)

 

$

0.30

 

 

$

0.04

 

 

$

(0.43

)

Net income (loss) attributable to common stockholders

0.23

 

 

(0.15

)

 

0.29

 

 

0.03

 

 

(0.42

)

 

 

 

 

 

 

 

 

 

 

Weighted average shares used in computing earnings per common share

 

 

 

 

 

 

 

 

 

Basic

375,067

 

 

374,669

 

 

374,473

 

 

373,177

 

 

372,982

 

Diluted

378,408

 

 

377,922

 

 

377,696

 

 

376,295

 

 

376,024

 


 

1Potential common shares are not included in the computation of diluted earnings per share when a loss from continuing operations exists as the effect would be an antidilutive per share amount.



 

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Dollars in thousands USD)

(unaudited)

 

For the Six Months Ended June 30,

 

2021

 

2020

Cash flows from operating activities:

 

 

 

Net income

$

32,890

 

.

$

315,495

 

Adjustments to reconcile net income to net cash provided by operating activities:

 

 

 

Depreciation and amortization

564,848

 

 

598,431

 

Amortization of deferred revenue and lease intangibles, net

(31,551

)

 

(6,334

)

Other non-cash amortization

10,119

 

 

9,653

 

Allowance on loans receivable and investments

(8,961

)

 

29,655

 

Stock-based compensation

21,465

 

 

11,557

 

Straight-lining of rental income

(7,167

)

 

91,499

 

Loss on extinguishment of debt, net

27,016

 

 

 

Gain on real estate dispositions

(43,791

)

 

(227,479

)

Gain on real estate loan investments

(74

)

 

(167

)

Income tax expense (benefit)

2,510

 

 

(95,127

)

(Income) loss from unconsolidated entities

(4,512

)

 

16,734

 

Distributions from unconsolidated entities

6,480

 

 

1,600

 

Other

(34,841

)

 

12,756

 

Changes in operating assets and liabilities:

 

 

 

Increase in other assets

(25,618

)

 

(12,463

)

(Decrease) increase in accrued interest

(5,732

)

 

7,094

 

Increase (decrease) in accounts payable and other liabilities

25,775

 

 

(32,893

)

Net cash provided by operating activities

528,856

 

 

720,011

 

Cash flows from investing activities:

 

 

 

Net investment in real estate property

(210

)

 

(77,469

)

Investment in loans receivable

(283

)

 

(67,290

)

Proceeds from real estate disposals

115,850

 

 

627,804

 

Proceeds from loans receivable

36,475

 

 

106,775

 

Development project expenditures

(130,894

)

 

(180,398

)

Capital expenditures

(74,122

)

 

(53,519

)

Investment in unconsolidated entities

(68,311

)

 

(7,865

)

Insurance proceeds for property damage claims

390

 

 

42

 

Net cash (used in) provided by investing activities

(121,105

)

 

348,080

 

Cash flows from financing activities:

 

 

 

Net change in borrowings under revolving credit facilities

(104,131

)

 

465,416

 

Net change in borrowings under commercial paper program

169,984

 

 

(565,524

)

Proceeds from debt

268,286

 

 

640,533

 

Repayment of debt

(565,951

)

 

(111,301

)

Payment of deferred financing costs

(17,776

)

 

(7,549

)

Issuance of common stock, net

14,250

 

 

 

Cash distribution to common stockholders

(337,838

)

 

(592,285

)

Cash distribution to redeemable OP unitholders

(3,164

)

 

(4,628

)

Cash issued for redemption of OP Units

(62

)

 

(570

)

Contributions from noncontrolling interests

30

 

 

346

 

Distributions to noncontrolling interests

(8,588

)

 

(6,293

)

Proceeds from stock option exercises

4,821

 

 

3,518

 

Other

(5,934

)

 

(4,891

)

Net cash used in financing activities

(586,073

)

 

(183,228

)

Net (decrease) increase in cash, cash equivalents and restricted cash

(178,322

)

 

884,863

 

Effect of foreign currency translation

1,450

 

 

(1,829

)

Cash, cash equivalents and restricted cash at beginning of period

451,640

 

 

146,102

 

Cash, cash equivalents and restricted cash at end of period

$

274,768

 

 

$

1,029,136

 

 

 

 

 

Supplemental schedule of non-cash activities:

 

 

 

Assets acquired and liabilities assumed from acquisitions and other:

 

 

 

Real estate investments

$

468

 

 

$

77,111

 

Other assets

 

 

614

 

Debt

 

 

55,368

 

Other liabilities

 

 

2,097

 

Noncontrolling interests

468

 

 

20,259

 




 


QUARTERLY CONSOLIDATED STATEMENTS OF CASH FLOWS

(Dollars in thousands USD)

(unaudited)

 

For the Three Months Ended

 

June 30,

 

March 31,

 

December 31,

 

September 30,

 

June 30,

 

2021

 

2021

 

2020

 

2020

 

2020

Cash flows from operating activities:

 

 

 

 

 

 

 

 

 

Net income (loss)

$

88,288

 

 

$

(55,398

)

 

$

111,953

 

 

$

13,737

 

 

$

(159,235

)

Adjustments to reconcile net income (loss) to net cash provided by operating activities:

 

 

 

 

 

 

 

 

 

Depreciation and amortization

250,700

 

 

314,148

 

 

261,966

 

 

249,366

 

 

349,594

 

Amortization of deferred revenue and lease intangibles, net

(16,785

)

 

(14,766

)

 

(15,513

)

 

(19,009

)

 

(3,361

)

Other non-cash amortization

4,847

 

 

5,272

 

 

5,508

 

 

5,558

 

 

5,802

 

Allowance on loans receivable and investments

(59

)

 

(8,902

)

 

(10,416

)

 

4,999

 

 

29,655

 

Stock-based compensation

5,393

 

 

16,072

 

 

4,165

 

 

5,765

 

 

1,043

 

Straight-lining of rental income

(3,304

)

 

(3,863

)

 

(4,052

)

 

15,635

 

 

98,287

 

(Gain) loss on extinguishment of debt, net

(74

)

 

27,090

 

 

3,405

 

 

7,386

 

 

 

Gain on real estate dispositions

(41,258

)

 

(2,533

)

 

(22,117

)

 

(12,622

)

 

(1,254

)

Gain on real estate loan investments

 

 

(74

)

 

 

 

 

 

 

Income tax expense (benefit)

2,007

 

 

503

 

 

(2,283

)

 

(4,575

)

 

55,146

 

(Income) loss from unconsolidated entities

(4,762

)

 

250

 

 

(17,701

)

 

(865

)

 

5,858

 

Distributions from unconsolidated entities

2,583

 

 

3,897

 

 

1,960

 

 

1,360

 

 

 

Other

(20,462

)

 

(14,379

)

 

(16,394

)

 

2,859

 

 

8,951

 

Changes in operating assets and liabilities:

 

 

 

 

 

 

 

 

 

(Increase) decrease in other assets

(20,518

)

 

(5,100

)

 

(5

)

 

(55,765

)

 

1,305

 

Increase (decrease) in accrued interest

14,502

 

 

(20,234

)

 

13,251

 

 

(20,069

)

 

30,126

 

Increase (decrease) in accounts payable and other liabilities

30,165

 

 

(4,390

)

 

(17,964

)

 

240,642

 

 

(16,358

)

Net cash provided by operating activities

291,263

 

 

237,593

 

 

295,763

 

 

434,402

 

 

405,559

 

Cash flows from investing activities:

 

 

 

 

 

 

 

 

 

Net investment in real estate property

 

 

(210

)

 

(1,023

)

 

(156

)

 

2,070

 

Investment in loans receivable

(97

)

 

(186

)

 

(2,016

)

 

(45,857

)

 

(66,239

)

Proceeds from real estate disposals

107,767

 

 

8,083

 

 

361,753

 

 

54,800

 

 

2,365

 

Proceeds from loans receivable

20,056

 

 

16,419

 

 

12,045

 

 

191

 

 

7,658

 

Development project expenditures

(72,296

)

 

(58,598

)

 

(70,446

)

 

(129,569

)

 

(86,169

)

Capital expenditures

(44,448

)

 

(29,674

)

 

(53,827

)

 

(40,888

)

 

(26,730

)

Investment in unconsolidated entities

(29,859

)

 

(38,452

)

 

(278,990

)

 

33

 

 

(2,056

)

Insurance proceeds (expense) for property damage claims

384

 

 

6

 

 

174

 

 

(9

)

 

 

Net cash used in investing activities

(18,493

)

 

(102,612

)

 

(32,330

)

 

(161,455

)

 

(169,101

)

Cash flows from financing activities:

 

 

 

 

 

 

 

 

 

Net change in borrowings under revolving credit facilities

(109,275

)

 

5,144

 

 

(14,724

)

 

(539,560

)

 

(2,296,737

)

Net change in borrowings under commercial paper program

(44,994

)

 

214,978

 

 

 

 

 

 

 

Proceeds from debt

237,129

 

 

31,157

 

 

75,741

 

 

17,024

 

 

557,774

 

Repayment of debt

(120,901

)

 

(445,050

)

 

(352,011

)

 

(16,227

)

 

(48,328

)

Purchase of noncontrolling interests

 

 

 

 

(8,239

)

 

 

 

 

Payment of deferred financing costs

(433

)

 

(17,343

)

 

(815

)

 

(15

)

 

(5,586

)

Issuance of common stock, net

3,175

 

 

11,075

 

 

18,967

 

 

36,395

 

 

 

Cash distribution to common stockholders

(169,075

)

 

(168,763

)

 

(168,446

)

 

(168,078

)

 

(295,981

)

Cash distribution to redeemable OP unitholders

(1,322

)

 

(1,842

)

 

(1,329

)

 

(1,326

)

 

(2,303

)

Cash issued for redemption of OP Units

(37

)

 

(25

)

 

 

 

(5

)

 

 

Contributions from noncontrolling interests

25

 

 

5

 

 

176

 

 

792

 

 

191

 

Distributions to noncontrolling interests

(5,935

)

 

(2,653

)

 

(3,280

)

 

(3,373

)

 

(3,750

)

Proceeds from stock option exercises

2,715

 

 

2,106

 

 

11,585

 

 

 

 

129

 

Other

(78

)

 

(5,856

)

 

53

 

 

(98

)

 

63

 

Net cash used in financing activities

(209,006

)

 

(377,067

)

 

(442,322

)

 

(674,471

)

 

(2,094,528

)

Net increase (decrease) in cash, cash equivalents and restricted cash

63,764

 

 

(242,086

)

 

(178,889

)

 

(401,524

)

 

(1,858,070

)

Effect of foreign currency translation

792

 

 

658

 

 

2,039

 

 

878

 

 

947

 

Cash, cash equivalents and restricted cash at beginning of period

210,212

 

 

451,640

 

 

628,490

 

 

1,029,136

 

 

2,886,259

 

Cash, cash equivalents and restricted cash at end of period

$

274,768

 

 

$

210,212

 

 

$

451,640

 

 

$

628,490

 

 

$

1,029,136

 




















 


QUARTERLY CONSOLIDATED STATEMENTS OF CASH FLOWS (continued)

(Dollars in thousands USD)

(unaudited)

 

For the Three Months Ended

 

June 30,

 

March 31,

 

December 31,

 

September 30,

 

June 30,

 

2021

 

2021

 

2020

 

2020

 

2020

Supplemental schedule of non-cash activities:

 

 

 

 

 

 

 

 

 

Assets acquired and liabilities assumed from acquisitions and other:

 

 

 

 

 

 

 

 

 

Real estate investments

$

 

 

$

468

 

 

$

1,000

 

 

$

92,373

 

 

$

76,578

 

Other assets

 

 

 

 

 

 

610

 

 

558

 

Debt

 

 

 

 

 

 

 

 

55,368

 

Other liabilities

 

 

 

 

 

 

610

 

 

1,699

 

Deferred income tax liability

 

 

 

 

 

 

337

 

 

 

Noncontrolling interests

 

 

468

 

 

 

 

 

 

20,068

 















 












 

NON-GAAP FINANCIAL MEASURES RECONCILIATION

Funds From Operations Attributable to Common Stockholders (FFO)1

and Funds Available for Distribution Attributable to Common Stockholders (FAD)1

(In thousands, except per share amounts; dollars in USD)

(unaudited)

 

 

 

 

 

 

 

 

Q2 YoY

 

 

 

 

2020

 

2021

 

Growth

 

 

 

 

Q2

Q3

Q4

 

Q1

Q2

 

’20-’21

 

YTD 2Q20

YTD 2Q21

Net (loss) income attributable to common stockholders

$

(157,170

)

$

12,751

 

$

110,451

 

 

$

(57,209

)

$

86,391

 

 

155

%

 

$

315,947

 

$

29,182

 

Net (loss) income attributable to common stockholders per share2

$

(0.42

)

$

0.03

 

$

0.29

 

 

$

(0.15

)

$

0.23

 

 

155

%

 

$

0.84

 

$

0.08

 

Adjustments:

 

 

 

 

 

 

 

 

 

 

 

Depreciation and amortization on real estate assets

348,110

 

247,969

 

260,705

 

 

312,869

 

249,527

 

 

 

 

595,440

 

562,396

 

Depreciation on real estate assets related to noncontrolling interests

(4,068

)

(4,475

)

(4,381

)

 

(4,618

)

(4,678

)

 

 

 

(7,911

)

(9,296

)

Depreciation on real estate assets related to unconsolidated entities

1,307

 

1,360

 

1,758

 

 

4,018

 

4,615

 

 

 

 

1,868

 

8,633

 

Gain on real estate dispositions

(1,254

)

(12,622